Reveal Biosciences – The First Certified Preclinical Services
Laboratory to Offer Advanced Cell Diagnostics RNAscope® In Situ
Reveal Biosciences, LLC, a leading preclinical services laboratory for advanced tissue technologies, is pleased to announce the availability of Advanced Cell Diagnostics’ (ACD) RNAscope® in situ hybridization (ISH) technology. With this collaboration, Reveal Biosciences becomes the first ACD Certified RNAscope® Service Provider to bring RNAscope® to researchers in the preclinical space.
RNAscope® is a novel RNA ISH technology that brings the benefits of in situ analysis to RNA biomarkers. This technology is compatible with FFPE specimens, conventional chromogenic and fluorescent dyes, and is suitable for bright-field microscopy and multiplex analysis. Although novel, this technology is already used in over 75 peer-reviewed publications in cancer, stem cell, neuroscience, and other applications. Reveal will combine the sensitivity of the RNAscope® assay with the power of ImageDx, their proprietary image analysis software, to provide quantitative ISH data from preclinical cell and tissue samples.
“Reveal Biosciences already delivers RNA data and quantification to pharmaceutical clients within preclinical oncology by combining RNAscope® with ImageDx, our proprietary image analysis software,” said Dr. Claire Weston, CEO and Founder of Reveal Biosciences. “We are thrilled to extend our portfolio of advanced tissue diagnostic services to offer RNAscope® technology to a wider range of pharmaceutical and biotechnology customers in oncology and other therapeutic areas. We believe RNAscope® technology, with its unique ability to deliver molecular detection while preserving morphological context in a single assay, will continue its trajectory in changing the landscape of RNA biomarker screening and validation in tissues for research, molecular diagnostics, and companion diagnostics.”
Advanced Cell Diagnostics introduced the Certified RNAscope® Service Provider program with the goal to enable laboratories to support pharmaceutical clients via delivery of high quality pathology testing services. Each service provider receives extensive training on RNAscope® technology and is required to pass a rigorous certification procedure. “The Reveal Biosciences team have proven themselves in automated immunohistochemistry, imaging, and image analysis. Their stellar reputation among researchers and comprehensive service portfolio makes them an ideal partner for deployment of our RNAscope® platform,” said Evangeline Gonzalez, Chief Commercial Officer at ACD.
About Reveal Biosciences
Reveal Biosciences is a leading contract research organization that specializes in advanced tissue technology services and tissue-based research. Their portfolio of services includes histology, immunohistochemistry (IHC), immunofluorescence (IF), proprietary multiplex technology, whole slide imaging, and image analysis/quantification, as well as novel RNA ISH technologies, such as RNAscope. Reveal Biosciences is also applying their expertise in advanced tissue technologies to develop innovative diagnostics and companion diagnostics. Learn more about Reveal Biosciences’ full range of advanced tissue technology services at http://www.revealbiosciences.com .
About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in molecular pathology, developing cell and tissue-based research tools for all areas of biomedical research, and diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope® technology, the most sensitive method available for RNA in situ hybridization capable of single molecule detection and multiplex analysis. RNAscope technology can turn RNA into powerful biomarkers by providing important molecular and morphological context that is lost with conventional analysis technologies. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope® technology at www.acdbio.com .